Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Redhill Biopharma Ltd is a drug manufacturers-specialty & generic business based in the US. Redhill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. Redhill Biopharma employs 201 staff and has a trailing 12-month revenue of around $83.4 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.52 |
|---|---|
| 52-week range | $0.47 - $6.50 |
| 50-day moving average | $0.89 |
| 200-day moving average | $1.65 |
| Wall St. target price | $7.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.10 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.52 from 2022-09-27
| 1 week (2022-09-21) | -14.75% |
|---|---|
| 1 month (2022-08-29) | -46.72% |
| 3 months (2022-06-29) | -38.82% |
| 6 months (2022-03-29) | -81.02% |
| 1 year (2021-09-29) | -88.60% |
|---|---|
| 2 years (2020-09-29) | -94.92% |
| 3 years (2019-09-27) | 7.24 |
| 5 years (2017-09-28) | 10.05 |
| Revenue TTM | $83.4 million |
|---|---|
| Gross profit TTM | $45.3 million |
| Return on assets TTM | -21.74% |
| Return on equity TTM | -385.03% |
| Profit margin | -110.31% |
| Book value | $0.17 |
| Market capitalisation | $33.2 million |
TTM: trailing 12 months
We're not expecting Redhill Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Redhill Biopharma's shares have ranged in value from as little as $0.473 up to $6.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Redhill Biopharma's is 1.8034. This would suggest that Redhill Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel. .
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.